StemCell Therapy

Shares ofProShares Ultra Nasdaq Biotechnology (BIB) have seen the needle move3.41% or 1.75 in the most recent session. TheNASDAQ listed companysaw a recent bid of $53.03 on83915 volume.

Strictly technical traders typically dont pay a whole lot of attention to fundamental factors such as value, competition, or company management. Technical analysts want to figure out trends based on indicators, charts, and prior price data. These types of traders are usually highly active and hold positions for short periods of time in order to capitalize on short-term price fluctuations. Active traders may be quick to unload a position if it does not pan out as expected. Technicians often pay a great deal of attention to support and resistance levels. These are levels where traders believe a specific stock will either see a bounce or a pullback.

Digging deeping into the ProShares Ultra Nasdaq Biotechnology (BIB) s technical indicators, we note that the Williams Percent Range or 14 day Williams %R currently sits at -54.70. The Williams %R oscillates in a range from 0 to -100. A reading between 0 and -20 would point to an overbought situation. A reading from -80 to -100 would signal an oversold situation. The Williams %R was developed by Larry Williams. This is a momentum indicator that is the inverse of the Fast Stochastic Oscillator.

ProShares Ultra Nasdaq Biotechnology (BIB) currently has a 14-day Commodity Channel Index (CCI) of -31.41. Active investors may choose to use this technical indicator as a stock evaluation tool. Used as a coincident indicator, the CCI reading above +100 would reflect strong price action which may signal an uptrend. On the flip side, a reading below -100 may signal a downtrend reflecting weak price action. Using the CCI as a leading indicator, technical analysts may use a +100 reading as an overbought signal and a -100 reading as an oversold indicator, suggesting a trend reversal.

Currently, the 14-day ADX for ProShares Ultra Nasdaq Biotechnology (BIB) is sitting at 20.96. Generally speaking, an ADX value from 0-25 would indicate an absent or weak trend. A value of 25-50 would support a strong trend. A value of 50-75 would identify a very strong trend, and a value of 75-100 would lead to an extremely strong trend. ADX is used to gauge trend strength but not trend direction. Traders often add the Plus Directional Indicator (+DI) and Minus Directional Indicator (-DI) to identify the direction of a trend.

The RSI, or Relative Strength Index, is a widely used technical momentum indicator that compares price movement over time. The RSI was created by J. Welles Wilder who was striving to measure whether or not a stock was overbought or oversold. The RSI may be useful for spotting abnormal price activity and volatility. The RSI oscillates on a scale from 0 to 100. The normal reading of a stock will fall in the range of 30 to 70. A reading over 70 would indicate that the stock is overbought, and possibly overvalued. A reading under 30 may indicate that the stock is oversold, and possibly undervalued. After a recent check, the 14-day RSI for ProShares Ultra Nasdaq Biotechnologyis currently at 47.24, the 7-day stands at 50.69, and the 3-day is sitting at 71.69.

See the original post here:
Shares Seesawing on Volume: ProShares Ultra Nasdaq Biotechnology (BIB) - Morgan Research

Puma Biotechnology Inc (PBYI) has ended the week in the black, yielding positive results for the shares at they ticked 1.66%.In taking a look at recent performance, we can see that shares have moved -15.83% over the past 4-weeks, 98.14% over the past half year and 57.11% over the past full year.

Traders are keeping a keen eye on shares of Puma Biotechnology Inc (PBYI). The Average Directional Index or ADX may prove to be an important tool for trading and investing. The ADX is a technical indicator developed by J. Welles Wilder used to determine the strength of a trend. The ADX is often used along with the Plus Directional Indicator (+DI) and Minus Directional Indicator (-DI) to identify the direction of the trend. Presently, the 14-day ADX is resting at 39.85. Generally speaking, an ADX value from 0-25 would indicate an absent or weak trend. A value of 25-50 would indicate a strong trend. A value of 50-75 would signal a very strong trend, and a value of 75-100 would indicate an extremely strong trend.

Some investors may find the Williams Percent Range or Williams %R as a helpful technical indicator. Presently, Puma Biotechnology Inc (PBYI)s Williams Percent Range or 14 day Williams %R is resting at -62.25. Values can range from 0 to -100. A reading between -80 to -100 may be typically viewed as strong oversold territory. A value between 0 to -20 would represent a strong overbought condition. As a momentum indicator, the Williams R% may be used with other technicals to help define a specific trend.

When performing stock analysis, investors and traders may opt to view technical levels. Puma Biotechnology Inc (PBYI) presently has a 14-day Commodity Channel Index (CCI) of -39.59. Investors and traders may use this indicator to help spot price reversals, price extremes, and the strength of a trend. Many investors will use the CCI in conjunction with other indicators when evaluating a trade. The CCI may be used to spot if a stock is entering overbought (+100) and oversold (-100) territory.

Checking in on moving averages, the 200-day is at 51.87, the 50-day is 86.05, and the 7-day is sitting at 79.11. Moving averages may be used by investors and traders to shed some light on trading patterns for a specific stock. Moving averages can be used to help smooth information in order to provide a clearer picture of what is going on with the stock. Technical stock analysts may use a combination of different time periods in order to figure out the history of the equity and where it may be headed in the future. MAs can be calculated for any time period, but two very popular time frames are the 50-day and 200-day moving averages.

Shifting gears to the Relative Strength Index, the 14-day RSI is currently sitting at 42.18, the 7-day is 40.31, and the 3-day is currently at 41.06 for Puma Biotechnology Inc (PBYI). The Relative Strength Index (RSI) is a highly popular momentum indicator used for technical analysis. The RSI can help display whether the bulls or the bears are currently strongest in the market. The RSI may be used to help spot points of reversals more accurately. The RSI was developed by J. Welles Wilder. As a general rule, an RSI reading over 70 would signal overbought conditions. A reading under 30 would indicate oversold conditions. As always, the values may need to be adjusted based on the specific stock and market. RSI can also be a valuable tool for trying to spot larger market turns.

See more here:
Puma Biotechnology Inc (PBYI): A Look at Recent Performance - FLBC News

Biology is a scientific branch from which emerged biotechnology, a multidisciplinary subject, which is growing fast in this modern world, having its impact on most of the activities in our day to day life. In simple terms, it is making products using living organisms. It is purely a research-oriented field, where the young minds who are interested in research can flourish. Biotechnology is a diverse field which benefits us in health, environment, industry, research, medical, agriculture and many more areas.

Although biotechnological impact was made in agricultural and industrial fields only in the early periods of the 20th century, it has its roots long back in BCs where beer, wine and bread were produced using single celled organisms via a process known as fermentation. Microorganisms were discovered later, who were the stepping stones to the modern biotechnological field. Karl Ereky, a Hungarian agricultural engineer, coined the term biotechnology. I can be a true biotechnologist only if I mention the two great names James Watson and Thomas Crick who discovered DNA in 1953, after which everyone came to know about the genetic material and how information passes at the molecular level. Later in 1970s, genes were manipulated by scientists, which led to the development of the wide area Genetic Engineering.

Green Biotechnology, Blue Biotechnology, White Biotechnology and Red Biotechnology are the fields which help us know more about the significance of biotechnology in agriculture, marine organisms, industrial products and medical processes. Improved varieties of crops are being produced which can better adapt to the existing environmental conditions. Flavr Savr tomato is a well known example. A better understanding of Blue Biotechnology helps us improve the seafood supply and safety. It is highly impossible to survive in the world without enzymes, the biological catalysts, which are produced through bioprocess technology utilising bioreactors and microorganisms. Thus, biotechnology has proved its importance in the industrial area too. In the medical field, biotechnology gains attention in gene therapy, production of humulin (recombinant insulin), recombinant vaccines etc. Drug designing and drug targeting has also gained too much interest in recent years with the advent of bioinformatics. Nanotechnology is also exploring the chances of developing and utilising nanoparticles for the benefit of mankind.

The future generation interested in this multidisciplinary field should plan a career accordingly from school days itself. It is always beneficial to opt for a biotech programme from the undergraduate level. After completing Masters in the respective branch, the young budding scientist can enter into the research field which leads to a doctoral degree that can be followed by post doctoral research. The job that can be taken up by biotechnologists is of a research scientist, and they can also be absorbed as a research associate, research assistants, laboratory technicians (food, water, environment labs, medical labs etc), teachers/lectures/professors, marketing personnel, business development officer, sales representative etc.

The door to the world of biotechnology is wide open. Lets enter it by contributing our the knowledge we have gained, which can improve and help sustain our life on earth.

Akhila RajanAsst Professor, Dept of Biotechnology, Waljat College of Applied Sciences

Read more from the original source:
From bio to biotechnology - Muscat Daily

VietNamNet Bridge Agricultural biotechnology is one of the key tools that can improve the yield and quality of agricultural products in a time of climate change, experts said.

Delegates meet at an APEC High-Level Policy Dialogue on Agricultural Biotechnology workshop in Can Tho on August 18-19. Photo: VNS

The experts were attending an APEC High-Level Policy Dialogue on Agricultural Biotechnology (HLPDAB) workshop in Can Tho on August 18-19.

Nguyen Thi Thanh Thuy, chair of the HLPDAB, and director general of the Ministry of Agriculture and Rural Developments Department of Science, Technology and Environment, said that Viet Nam, like many other economies, was facing multiple challenges due to climate change, including shrinking agricultural area and land degradation caused by urbanisation and saline intrusion caused by rising sea levels.

Many localities are suffering severe consequences of extreme weather, such as heavy rains, floods, flash floods, coastal shoreline erosion and salinity intrusion. These are threatening peoples livelihoods and agricultural production, she said.

Viet Nam has identified its response to climate change as one of the key tasks of its entire political system.

Strengthening international dialogue and co-operation in response to climate change is a priority set by the Government. This includes encouraging the use of new innovative technologies to promote sustainable agriculture, in which agricultural biotechnology is one of the key tools.

Speaking on the sidelines of the workshop, Pham Van Toan, associate professor at the Viet Nam Academy of Agricultural Sciences, said climate change, drought and saline intrusion were seriously affecting agricultural production.

With biotechnology, we can create drought-resistant and saline-resistant varieties to help the agricultural sector make products that meet market demand and food security, he said.

Biotechnology can help create new crop varieties that adapt to climate change and reduce greenhouse gas emissions, and especially helps improve the efficient usage of nutrients of crop plants, he said.

Globally, more than 400 genetic modification events (an insertion of a particular transgene) had been approved for food and animal feed, he said, adding that more than 20 events (maize and soybean) had been approved in Viet Nam.

Viet Nams biotechnology industry had begun development 20 years ago, but its achievements remained modest, he said.

Tomorrow, the annual meetings of the Ocean and Fisheries Working Group and the APEC High Level Policy Dialogue on Agricultural Biotechnology will be held.

Source: VNS

Read more:
Experts urge use of agricultural biotechnology as response to climate change - VietNamNet Bridge

A labourer sifts wheat crop in a field. PHOTO: REUTERS

LAHORE:There is a dire need for increasing the agricultural yield to feed an increasing global population, food security experts emphasised on Saturday, highlighting biotechnology and its sub-fields as the key to increasing the productivity per acre.

Remedies derived from biotechnology could allow crop adaptation to biotic and abiotic stresses arising due to massive climate change at the global level, they said, adding technologies like genetic engineering could transform agricultural practices massively to make the sector more productive.

Food Security Policy: PARC finalises draft for cabinet review

Biotechnology is playing an important role in mitigating adverse impacts of climate change on agricultural output by reducing emission of greenhouse gases, said Professor of Biotechnology at FCC University Lahore Dr Kauser Malik.

He said the use of biofuels, for example, would help solve energy supply problems by providing renewable and cheap energy for farmers, apart from reducing the adverse impact of carbon dioxide emissions.

Carbon dioxide emissions are reduced by using traditional and genetically modified crops such as sugarcane, oilseed and rapeseed, he said, adding the need for tillage could also be reduced with the help of genetically modified crops.

We can modify plants through genetic engineering so that they absorb relatively more carbon from the atmosphere and convert it into oxygen. Soil fertility can also be increased by mixing microbes in the soil. In this context, modern environmental biotechnology has gained immense importance in coming up with innovative ways of increasing productivity, Malik said.

Experts claim that rainfall volatility, increasing drought conditions and drastic rises in temperatures all symptoms of climate change affect food production and are also responsible for pest, disease and weed outbreaks in crops.

Fast-paced climate change, experts claim, is not providing crops enough time to adjust to the changing environment, thereby stifling growth. According to an estimate, in 20 to 25 years, the world will get to a point where climatic conditions in most fertile areas will become too extreme for growing crops.

Pakistan Agriculture Research Council: Govt dept fires 500 employees

Malik said under the circumstances, increasing the area under production and improving productivity on the existing farmland were the only two choices to overcome food security challenges and adapt to changing climatic conditions.

Transgenic canola and soybean have been modified to be resistant to specific herbicides. Fungi, bacteria and virus-resistant GM cassava, potatoes, bananas and other crops are also being developed with some having already been commercialised while others are undergoing field trials, he added.

Published in The Express Tribune, August 20th, 2017.

LikeBusiness on Facebook, follow @TribuneBizon Twitter to stay informed and join in the conversation.

See more here:
Food security experts shift focus to biotechnology - The Express Tribune

Finnish Mets Group has started its mill for bio-based products. The 1.2bn investments production capacity is 1.3 million tonnes of softwood pulp a year.

According to the Finnish company, pulp deliveries from the new mill to customers will begin in early September 2017. Mets said that its old pulp mill in nekoski has been shut down and is currently be dismantled.

The new mill will achieve its nominal capacity approximately a year after start-up. Mets Group will be the worlds biggest producer of softwood pulp, said Ilkka Hml, CEO of Mets Fibre. The mill will produce 1.3 million tonnes of pulp per year, along with other bio-based products such as tall oil and turpentine. New bioproducts include product gas from bark, sulphuric acid from the mills odorous gases, and biogas and biofuel pellets from sludge.

The mill will be a platform for production of new bio-based products among them lignin products, textile fibres, and biocomposites. The next-generation bioproduct mill will not use any fossil fuels at all, since it will generate all of the energy that it needs from side streams. In terms of its energy efficiency, the mill is among the world's best within its industry. Its degree of self-sufficiency in electricity is 240 per cent.

Follow this link:
Mets Group started up its bioproduct mill - European Biotechnology

Needle moving action has been spotted in Prana Biotechnology Ltd (PBT.AX) as shares are moving today onvolatility0.00% or $0.00 from the open.TheASX listed companysaw a recent bid of $0.055 and155324shares have traded hands in the session.

Some investment professionals believe that a great way to find, study, and invest in equities without getting completely overwhelmed, is to have a systematic and research driven approach. Of course, the same approach may not work for everybody. One investor may find one way that works for them, and another investor might find something completely different when it comes to portfolio picking. Trading and investing can carry a major emotional component. Even after careful research, being able to pull the trigger on a trade may still involve squashing the fear that comes with the thought of being wrong. Finding continued success in the stock market may entail keeping the portfolio balanced, but also finding the courage to get in when necessary, or get out when needed. Developing this confidence may take a lot of practice and determination.

Now letstake a look at how the fundamentals are stacking up for Prana Biotechnology Ltd (PBT.AX). Fundamental analysis takes into consideration market, industry and stock conditions to help determine if the shares are correctly valued. Prana Biotechnology Ltd currently has a yearly EPS of -0.02. This number is derived from the total net income divided by shares outstanding. In other words, EPS reveals how profitable a company is on a share owner basis.

Another key indicator that can help investors determine if a stock might be a quality investment is the Return on Equity or ROE. Prana Biotechnology Ltd (PBT.AX) currently has Return on Equity of -26.73. ROE is a ratio that measures profits generated from the investments received from shareholders.

In other words, the ratio reveals how effective the firm is at turning shareholder investment into company profits. A company with high ROE typically reflects well on management and how well a company is run at a high level. A firm with a lower ROE might encourage potential investors to dig further to see why profits arent being generated from shareholder money.

Another ratio we can look at is the Return on Invested Capital or more commonly referred to as ROIC. Prana Biotechnology Ltd (PBT.AX) has a current ROIC of -26.73. ROIC is calculated by dividing Net Income Dividends by Total Capital Invested.

Similar to ROE, ROIC measures how effectively company management is using invested capital to generate company income. A high ROIC number typically reflects positively on company management while a low number typically reflects the opposite.

Turning to Return on Assets or ROA, Prana Biotechnology Ltd (PBT.AX) has a current ROA of -24.71. This is a profitability ratio that measures net income generated from total company assets during a given period. This ratio reveals how quick a company can turn its assets into profits. In other words, the ratio provides insight into the profitability of a firms assets. The ratio is calculated by dividing total net income by the average total assets.

A higher ROA compared to peers in the same industry, would suggest that company management is able to effectively generate profits from their assets. Similar to the other ratios, a lower number might raise red flags about managements ability when compared to other companies in a similar sector.

Read more:
Prana Biotechnology Ltd (PBT.AX) A Look Inside the Technicals - Morgan Research

Dr. Dwayne E. Carter,Post Doctoral Researcher, Tissue Applications.

(PRESS RELEASE) A national of Grenada, Dr. Dwayne E. Carter received his formation in the sciences at the Grenada Boys Secondary School and the T. A. Marryshow Community College in his hometown of Saint Georges.

Dwayne would later migrate to the United States to further pursue his passion for medicine and his curiosity to better understand and cure diseases that plague the human race. After years of study, Dwayne completed his doctoral training in cell biology at the University of Texas Medical Branch where he primarily focused on acute alcohol induced liver injury.

In 2016, he joined ORGANOVO Holdings Inc. as a post-doctoral researcher in liver tissue bioengineering with a focus on modeling progressive liver diseases. Throughout his graduate training, Dwayne received numerous awards for meritorious research from national scientific meetings and has two publications in peer reviewed journals.

When asked about the advice that he would give to young persons in the sub region that may be interested in an investigative science career, Dwayne said: This is a long road but the journey is worth it. A tip is to always make goals for yourself and plan strategic ways to achieve those goals.

Also be prepared to fight for what you want! Very few things are handed to you in this world, so brace yourself for times of adversity because you will inevitably be faced with challenges and the way you deal with them determines your success or failure.

At this stage in my life I consider myself a fighter, I look forward to the challenges because Ive learnt that they bring forward my best, he said.

Dr. Carter will be delivering a presentation on Modeling Human Biology, Drug Response and Progressive Liver Disease Using 3D Bioprinted Human Liver Tissue at the Committee Lecture Hall at TSRI, La Jolla, California at 7:00pm today, August 16, 2017.

ABOUT THE PRESENTATION:

Nonalcoholic fatty liver disease (NAFLD) is a chronic condition that originates as lipid accumulation within hepatocytes (steatosis) and progresses into nonalcoholic steatohepatitis (NASH), characterised by lipid accumulation, inflammation, oxidative stress, and fibrosis. NAFLD is now recognised as the most common cause of chronic liver disease, with a prevalence of 25% worldwide, and is projected to become the leading indication for liver transplant by 2025.

Despite decades of research in rodents and 2D cell cultures, the mechanisms of NAFLD progression, therapeutic approaches and non-invasive diagnostics are still resoundingly absent. Thus, there is a significant need for a more predictive human multicellular 3D in vitro model to study the progression of steatosis into NASH.

Using immune competent ExVive Human Liver Tissue, an in vitro 3D bioprinted liver, Dr. Carter will show preliminary data where the key features of NASH such as steatosis, fibrosis and inflammation will be modeled via nutrient overload followed by inflammatory stimulation using prototypical inducers.

ABOUT THE OECS FEATURE SERIES:

The OECS Feature Series is an initiative that seeks to feature the accomplishments of consummate professionals from OECS Member States making strides within the region and in the Diaspora.

The project highlights one outstanding OECS national per month and aims to inspire the regions youth to think big and open their minds to extraordinary possibilities through the success stories of their OECS peers.

Criteria for nominations include: being a national of an OECS Member State; possessing an academic distinction of the highest order; scientific invention; high political accomplishment (regionally and in the Diaspora); and extraordinary community or national service achieved (regionally and in the Diaspora).

This article was posted in its entirety as received by stlucianewsonline.com.This media house does not correct any spelling or grammatical error within press releases and commentaries.The views expressed therein are not necessarily those of stlucianewsonline.com, its sponsors or advertisers.

See the rest here:
OECS highlights outstanding Grenadian making strides in biotechnology - St. Lucia News Online

LAS VEGAS, August 15, 2017 /PRNewswire/ --

The healthcare sector is made up of several different industries, from pharmaceuticals to biotechnology to health insurance. Making predictions in this sector can be difficult as there are many variables working with and against each other at one time. It's important to track both negative and positive trends in healthcare companies. Investors who track these trends, make the best out of their predictions.

Certain trends in healthcare an investor should track include: the aging population and their healthcare needs, personalized medicine, the global reach of certain diseases, obesity and diabetes epidemic, and of course, technological advances. All of these trends mean different things in healthcare stock. Biotech companies are working tirelessly to address specific trends in human health, identifying the companies who are working with healthcare trends is key.

Some such companies include: Endonovo Therapeutics, Inc. (OTC: ENDV), Juno Therapeutics, Inc. (NASDAQ: JUNO), Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), Genocea Biosciences, Inc. (NASDAQ: GNCA), and TherapeuticsMD, Inc. (NYSE: TXMD)

Endonovo Therapeutics, Inc. (OTCQB: ENDV)

Market Cap: $7.3M, current share price: .028

ENDV is an innovative biotechnology company implementing a bioelectronic approach to regenerative medicine. They are addressing several healthcare trends with their electroceutical platform, which is a non-invasive, non-implantable device for treating inflammatory conditions in vital organs. Through the innovative research at ENDV, they are addressing most of the major healthcare trends by developing therapies to treat the aging population and addressing obesity and the complications that it entails, such as peripheral artery disease, heart disease, diabetic kidney disease and non-alcoholic steatohepatitis (NASH). Additionally, ENDV is working to address global diseases, kidney disease, and organ failure.

Tracking ENDV and their work in research and development (R&D) is something anyone interested in healthcare or biotech stocks should do. As their research correlates and ebbs and flows with healthcare trends. Some highlights regarding ENDV's R&D are below:

As ENDV moves forward and inches closer to announcing the results of their pre-clinical studies across their diverse technology platform, you'll want to stay up-to-date with their successes.

Other healthcare and biotech companies to review

Juno Therapeutics, Inc. (JUNO)

Market Cap: $3.021B, current share price: 28.30

JUNO, a clinical-stage cell immunotherapy company focused on revolutionizing medicine by re-engaging the body's immune system to treat cancer, has achieved recent milestones with its collaboration with Editas Medicine, Inc. (EDIT) This collaboration began over two years ago, the two companies are pursuing three research programs that aim to combine Editas Medicine's genome editing platform with Juno's CAR and TCR technologies.

Their most recent achievement relates to the improvement in the ability of T cells to overcome the tumor microenvironment. Editas Medicine will receive $2.5 million for achieving this milestone.

Eleven Biotherapeutics, Inc. (EBIO)

Market Cap: $35.2M, current share price: 1.425

EBIO is a late-stage clinical oncology company advancing a broad pipeline of novel product candidates based on its Targeting Protein Therapeutics (TPTs) platform. They announced this week that they'll be hosting a live conference call to announce their Q2 financial results.

This is scheduled for 8:00 a.m. ET on Monday, August 14, 2017. To access the conference call, please dial (844) 831-3025 (domestic) or (315) 625-6887 (international) at least five minutes prior to the start time and refer to conference ID 63779857.

Genocea Biosciences, Inc. (GNCA)

Market Cap: $112.74M, current share price: 3.955

Similarly to JUNO and EDITS collaboration on moving research forward regarding T cells, GNCA's lead candidate is a novel T cell-directed immunotherapy for genital herpes. Today marks a horrible day for GNCA's performance on the stock market. GNCA's shares closed down 7.42% on Thursday with a little over 600,000 shares traded. The company reported second quarter financial results this week and reported a loss of $15.4 million.

On a per share basis, this was a loss of 54 cents while Wall Street was only expecting a loss of 46 cents. Keep a lookout for this stock as its performance is expected to continue to plummet.

TherapeuticsMD, Inc. (TXMD)

Market Cap: $1.15B, current share price: 5.630

TXMD, an innovative women's healthcare company, just received a formal General Advice Letter from the FDA stating that an initial review has been completed and requesting that the Company submit the additional endometrial safety information to the NDA for TX-004HR on or before September 18, 2017.

This is great news for TXMD although they've been ranked negatively in the HealthCare Sector. Investors who seek profit from falling equity prices should target TXMD. Short interest is extremely high for TXMD with more than 20% of shares on loan.

Microcap Speculators

Email: rel="nofollow">info@microcapspecualtors.com

Phone: +1-702-720-6310

Website: http://microcapspeculators.com/

DISCLAIMER: Microcapspeculators.com (MS) is the source of the content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM) is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with MS or any company mentioned herein. The commentary, views and opinions expressed in this release by MS are solely those of MS and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable MS and FNM for any investment decisions by their readers or subscribers. MS and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

MS Disclosure: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns Microcapspeculators.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC. which owns, Microcapspeculators.com may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC. which owns Microcapspeculators.com may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. For Full Legal Disclaimer Please use this link:http://microcapspeculators.com/disclaimer/

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MS and FNM undertake no obligation to update such statements.

Media Contact

FN Media Group, LLC

rel="nofollow">editor@financialnewsmedia.com

+1-(954)-345-0611

Read this article:
Tracking Trends in Biotechnology - Markets Insider

By Nkechi Isaac

Maize (also known as corn in some countries) is one of the most common and important food crops across Africa. It is widely eaten in various forms and more than 900 million Africans depend on maize every year because it is often cheaper than rice and wheat, two of the other most consumed cereals.

A report released by the IITA estimates that about 800 million tons of maize is produced worldwide every year.

According to the report, though the United States remains the worlds largest producer with 42 percent of all maize produced globally, Africa contributes significantly in this production with 6.5 percent of this volume which is still insufficient for local consumption.

Nigeria remains Africas largest producer with nearly 8 million tons per annum. It is closely followed by South Africa, Tanzania, Kenya and Uganda.

It was therefore a nightmare when Nigeria like the rest of Africa woke up to the Fall Armyworm (FAW) infestation which was rapidly spreading across the region.

Army worm is very deleterious and like the name suggests it derives its name from its feeding habits, of marching in large numbers from grasslands into crops. They strongly prefer grasses, cereals like maize, and can mercilessly eat the stem of the crop as well as the leaves.

Army worm infestation can be disastrous on the crops. It affects the yield of the crop from the stalk to the stage of maturity and is capable of destroying entire crops in a matter of weeks if it is unchecked.

Like other African countries, Nigeria woke up to a nightmare of recent army worm infestation in the region, leaving farmers worried as the pest, which has grown resistance to chemicals, wreaked havoc on newly cultivated maize farms across the country. This resulted in the severe reduction on the yield recouped by farmers on their maize field.

The Federal Government quickly waded and convened a meeting with commissioners for agriculture from the 36 states in Abuja to find ways of ameliorating the effect of the havoc and contain the infestation.

In his speech, the Minister of Agriculture and Rural Development, Chief Audu Ogbeh, said the achievement of self-sufficiency in maize production would continue to be a mirage with the pest infestation.

He said the spread of the maize disease had negatively affected the poultry industry, which largely depends on maize for the production of feeds.

The minister explained that the aim of the meeting was to brainstorm on ways of finding sustainable solutions to the army worm infestation which had ravaged maize farms in the states.

It is the state government that owns lands; so we need to tackle this problem to boost agricultural production, he said.

Ogbeh told the meeting the federal government required N2.98 billion to curb the army worm infestation of farmlands across the country, adding the United Nations Food and Agriculture Organisation (FAO) had pledged to support the country in its fight against the army worm infestation.

However, scientists are calling on farmers to embrace biotechnology by using genetically modified crops which have been proven safe for man and the environment to permanently tackle such occurrences.

Speaking during an interview with journalists in Abuja, the country coordinator of Open Forum on Agricultural Biotechnology (OFAB), Nigeria Chapter, Dr Rose Gidado, said genetic modification, also known as genetic engineering, is a technologically advanced way to select desirable traits in crops, pointing out that while selective breeding has existed for thousands of years, modern biotechnology is more efficient and effective because seed developers are able to directly modify the genome of the crop.

The OFAB coordinator said adopting genetic modification technology to develop maize variety resistant to pest provided a lasting solution for army worm infestation, adding genetically engineered (GE) plants are selectively bred and enhanced with genes to withstand common problems that confront farmers which include maize that could survive pesticides/infestation.

Gidado, a deputy director, at the National Biotechnology Development Agency (NABDA) revealed that a breakthrough recorded by scientists with the development of a maize variety called Water Efficient Maize for Africa (WEMA) which has proven to resist the attacks from army worm infestations provided a lasting solution to the infestation.

She said: The lasting solution to army worm infestation on maize is the use of genetic modification technology to develop a maize variety that would be resistant to the pest, that gives a permanent solution.

She added, There is already a variety of maize called Water Efficient Maize Variety for Africa that has proven to be resistant to army worm, it has not yet been deployed to Nigeria but we are making plans.

The WEMA project is a public-private partnership to develop royalty-free African drought-tolerant white maize varieties, it also increases yield stability, protects and promotes farmers investment in best management practices.

The project which is water conserving and insect protected conventional and transgenic maize, is expected under moderate drought, to increase yields by 20-35 percent over current varieties; it is also expected to translate into additional 2 million MT of maize during drought to feed 14 to 21 million people.

Like Loading...

Related

Go here to see the original:
Biotechnology, Panacea To Army Worm Maize Infestation - Leadership Newspapers

By Abdallah el-Kurebe

With the down turn in the global prices of oil, we now have to prospect our solid minerals. We have to return to agriculture, President Buhari to members of the Council of Saudi Arabian Chambers of Commerce and Industry.

According to the United Nations projections, the world population will be 9.8 billion people by 2050 and Nigeria which currently ranks seventh, will become the third most populous, replacing United States. It is currently about 200 million people.HARVEST: Women with baskets of tomatoes harvested from farmlands provided under the Restoring Agricultural Assets of IDPs, Returnees and Vulnerable Host Families in NorthEast Nigeria project, put together by the Food and Agriculture Organisation of the United Nations; the UN Central Emergency Response Fund and the governments of Ireland, Japan and Belgium.

Since his assumption of office in May 2015, President Muhammadu Buhari has repeated said that the nations economy must be diversified to, especially Agriculture which must cease from being treated as development programme but be treated as business. Our goal will be to pursue government supported private sector agriculture value chain to make agriculture more productive, efficient and competitive.

The drastic fall of oil prices in the international market has directed the thinking of the Buhari administration to diversify the economy to, specifically agriculture and one possible means of doing this is the deployment of biotechnology.

It serves as a tool for sustainable development in agriculture and could boost food security in Nigeria. It is therefore appropriate for the country in order to boost the production of maize, cotton, rice, beans, wheat, cassava, etc to, not only meet up with our consumption needs but also for the purpose of commercialization.

Dr. Muhammad Lawan Umar, a plant breeder with Institute for Agricultural Research of Usmanu Danfodiyo University, Zaria observes that Biotechnology has made possible what was impossible for the traditional methods to make by use of the new techniques. This has become realisable, especially I advanced countries, where such technology has been adopted and it can work wonders for developing countries, like Nigeria.

He gives an example of the pod-borer resistant beans on which efforts had been made to discover the source of the resistance without success. So far, 15,000 different types of varieties have been assembled and screened in order to identify the cause of the resistance. Experts agreed that the only option is to use biotechnology, which has now identified the maruca-resistant beans. This was a global phenomenon from America down to Africa where the problem of maruca is more, he said.

Umar adds that tests have been conducted in West Africa (Ghana, Nigeria and Burkina Faso) where traits that were resistant to those insects have been identified.

Biotechnology been used to transfer the genes to farmer-specified varieties adapted to different ecology in these West African countries. We have realised four to five times increase in yields and we are moving towards commercialisation.

Secondly, biotechnology has shortened the time of developing and releasing a variety. This is done in three to four years if there are no regulatory agencies that may delay the process. With the use of molecular marker, you can select a plant at a tender stage in fact you can select a grain to see which one carries the gene or not. But with the conventional methods, we used to spend eight to nine years to develop and release a variety because we had to plant it, grow it and then harvest it before you can assess, he explained.

Adebayo Olusoji, an Agriculture Extension and Rural Development Expert with the Oyo State College of Agriculture and Technology, Igboora said that biotechnology is an innovation has done well for Nigerias cassava production. Presently, we have more than twenty genetically modified improved cassava varieties with an average yield of 25-45 tonnes per hectare.

He adds that in cassava value chain, processing of improved cassava has resulted in high quality starch, which is being exported abroad. Biotechnology has not left out annual crops like maize, soybean, etc. As we have pro-vitamin A maize, Alfa toxin free soybean, etc.

A good step is Nigerias adoption of biotechnology in agriculture through the Biotechnology Policy, which led the establishment of the National Biotechnology Development Agency (NABDA). And in order to address safety concerns, the National Bio-safety Management Agency (NBMA), a full-fledged agency that provides regulatory frameworks for sustainability has been established.

Prof. Lauwali Abubakar, the Director at the Centre for Agricultural and Pastoral Research of the Usmanu Danfodiyo University, Sokoto said that Nigerias population growth was against the low agricultural productivity. Our population is expanding while our agricultural production is low. We need biotechnology, which will bring multiple food production in a limited period.

Hamma Ali Kwajaffa is former President of the National Cotton Association of Nigeria (NACOTAN) and Director General at Nigerian Textile Manufacturers Association said that biotechnology could develop African cotton, especially now that the product is in completion in the international market.

Biotechnology has increased the tonnage of cotton per hectare in America, China and India and their farmers are happy with it. We have not been able to achieve one tonne per hectare in Nigeria while those using biotechnology are harvesting five tonnes per hectare. Generally, our farmers have been left out, he said.

He cited Burkina Faso as the number country in Africa that applied biotechnology on commercial level for cotton. When Nigeria starts full application of biotechnology after field trials, the story will be a different one. Biotechnology will boost our agricultural productivity in no small measure.

Thanks to biotechnology, India which was least known in agriculture became worlds largest producer of cotton; Argentina leads in the production and export of soybeans and Burkina Faso, in the last two years became Africas largest producer of BT cotton.

Therefore, Nigeria has no choice than to consider the deployment of agricultural biotechnology, especially if food insecurity is our concern against the projected population explosion.

Read more:
How biotechnology can optimize agriculture in Nigeria - Vanguard

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Monday, August 7.

Philip Morris International (NYSE:PM): "No, don't sell it. I think they have a lot more optionality. I would not sell that here. And remember, I think the dollar's getting very weak still."

Blue Apron (NYSE:APRN): Cramer doesn't see upside.

International Game Technology (NYSE:IGT): It's an inexpensive stock but does not have a growth catalyst.

Eaton Corp (NYSE:ETN): Their quarter was not good. Cramer prefers Honeywell (NYSE:HON) or 3M (NYSE:MMM).

DaVita (NYSE:DVA): No. Cramer prefers Boston Scientific (NYSE:BSX) in that group.

Puma Biotechnology (NYSE:PBYI): It has had a big run. Book profits.

Masimo Corp (NASDAQ:MASI): Cramer just prefers Intuitive Surgical (NASDAQ:ISRG) in that group.

::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

Jim Cramer's Action Alerts PLUS: Check out Cramer's multi-million dollar charitable trust portfolio and uncover the stocks he thinks could be HUGE winners. Start your FREE 14-day trial now!

Get Cramer's Picks by email - it's free and takes only a few seconds to sign up

More here:
Book Profits On Puma Biotechnology - Cramer's Lightning Round (8/7/17) - Seeking Alpha

Two entities that seem like they should be on the same page a coalition of environmental groups and a plant-based food company are at odds.

And the flash point is a veggie burger.

Impossible Foods is facing scrutiny about the safety of a key ingredient in its trademark Impossible Burger, commonly known as the veggie burger that bleeds.

The controversy arose when theNew York Timespublished an article highlightingcorrespondencebetween the FDA and Impossible Foods that environmental groups say indicates that the protein had not met the agencys approval before going to market about a year ago.

Currently our FDA, EPA and USDA regulations are falling behind the very quickly moving development of new technologies, and one of the ways that our regulatory agencies are falling behind is they are not assessing the process of genetically engineering these ingredients, said Dana Perls of Friends of the Earth, one of the groups that raised concerns about Impossible Foods safety testing.

[Read the GLPs profile on Friends of the Earth.]

[The companys CEO and founder, Patrick Brown] said the groups objections are more about the use of biotechnology than the product itself.

The vast majority of their effort is an antiscience, anti-GMO crusade, Brown said. Their strategy has tended to be to try to effectively take down any company that is using biotechnology by whatever means they can come up with.

[Editors note: Below is a letter by Impossible Burger CEO and founder Patrick Brown, republished in full with permission from the company.]

The New York Times published an Aug. 8 article falsely implying that Impossible Foods is trying to evade US Food and Drug Administration regulations and putting consumers at risk by selling a product (the Impossible Burger) containing soy leghemoglobin. The article was chock full of factual errors and misrepresentations and was instigated by an extremist anti-science group with the deliberate intention of damaging our reputation.

Heres the truth:

The greatest threat the world faces today is the enormously destructive impact that our use of animals as a food technology has on climate, water, wildlife and biodiversity, global food security and political stability. Although little known to the public and almost completely ignored by the news media, this threat is well recognized by environmental and climate scientists and organizations including the UN Environmental Program, the UN Food and Agriculture Organization, and the Union of Concerned Scientists, among many others. The problem is not going to be solved by asking that people give up, or even reduce, consumption of the animal-derived foods they love; the demand for meat, fish and dairy foods is growing even faster than the human population. Nothing is more important to the planet our children and future generations will inherit, or their quality of life, than finding a solution to this dilemma.

Thats why I founded Impossible Foods. Our singular mission is to enable the world to continue to enjoy the foods they love and increasingly demand, without catastrophic damage to the environment. Our strategy was simple: invent a better way to transform plants into delicious, nutritious, safe and affordable meat, fish and dairy foods that consumers love. Then let consumers choose. If we do our job right, the market will take care of the rest. Commitment to the health, nutrition and safety of our customers is an inseparable part of our mission; its at the heart of why we exist, embedded in our ethos and everything we do.

With support from investors who understand and believe in our mission, we built a team of scientists who have worked tirelessly on this problem, understanding meat what underlies its flavor, texture and all its physical properties far better than it was ever understood. One of many discoveries they made, perhaps the most important, is that a molecule called heme is what makes meat taste like meat. Without heme, you cant make meat that will satisfy the billions of people who love meat.

Heme is an iron-containing molecule thats essential for life on Earth. Its found in every living organism. Its the magic molecule that enables the cells in our bodies and in every living being on Earth to benefit from the oxygen in our atmosphere. Its the molecule that carries oxygen in our blood, makes our blood red and our lips pink. Because its in every plant and animal, humans have been eating heme every day since the first human walked on Earth. The reason that animal tissues (meat) tastes like meat and unlike any vegetable, is that animal tissues contain hundreds to thousands-fold more heme than plant tissues.

To accomplish our essential mission, we needed to find a safe way to produce heme without using animals. We used yeast cells, into which we introduced a plant gene encoding a protein called soy leghemoglobin thats naturally found in the roots of soy plants. The heme in the Impossible Burger is atom-for-atom identical to the heme found in meat, fish, plants and other foods. Soy leghemoglobin carries the heme molecule in the same way a very similar protein, myoglobin, carries heme in muscle tissue (meat). Myoglobin is just one of the thousands of different heme proteins we all consume safely in our diets every day.

The health and safety of our customers is our first priority. The foods in our diet and the molecules and ingredients they contain are by default presumed to be safe, but only a minuscule fraction have ever been scientifically tested for their safety. Although there was never a reason to suspect that soy leghemoglobin would pose any more risk than myoglobin, or any of the new proteins we encounter in our diet all the time, we started four years ago to do a deep scientific study of its safety, including any potential for toxicity or allergenicity. The data we collected and our analyses were documented and reviewed by three independent food-safety experts in toxicology, allergenicity and yeast. In 2014, this expert panel unanimously concluded based on all the evidence that the protein is generally recognized as safe (GRAS) for human consumption. This is the approach followed by thousands of food companies to meet the FDA requirement that foods be generally recognized as safe. But we did more.

There is no legal or regulatory requirement that a companys finding of GRAS be submitted to the FDA for review. And its frequently not done. In fact, a total of only 709 have been submitted since the GRAS Notification system was put in place almost 20 years ago in 1998. But we did it because we recognize and respect the value of the FDA as guardian of the safety of the American food supply, one of the safest in the world.

We wanted the FDA to review our GRAS determination, to have the added benefit of their expertise, and to assure consumers that our testing of leghemoglobin has passed the most rigorous scrutiny. After submitting our GRAS determination, the FDA reviewed it, and had some questions. To address them, we conducted additional tests. And the tests turned out just as we expected: no adverse effects in rats consuming leghemoglobin every day for a month at levels more than 200 times what an average American would consume if all the ground beef in their diet were the Impossible Burger, and very low risk of allergenicity. A panel of the worlds leading experts in food safety and allergenicity has reviewed the new data, as well as the data originally submitted.

The expert panel has again unanimously concluded that soy leghemoglobin is safe; it is GRAS.

Impossible Foods has always worked constructively with the FDA, whose role as guardian of food safety for the nation we deeply respect. We will be submitting the additional data, along with the expert panels analysis of it, to the FDA this month. And FDA will make Impossible Foodss submission hundreds of pages of safety and allergenicity test results and the expert analysis of those results publicly available on its web site soon thereafter. In addition, in an abundance of caution, we clearly label our product as containing potential allergens: wheat and soy also in compliance with federal regulations. Finally, restaurants where the Impossible Burger is sold also comply with federal regulations about labeling.

Impossible Foods is proud of the safety of its first product, the Impossible Burger, and is committed to the health and safety of our customers. Thats why weve gone far beyond merely complying with food safety regulations, and we always will. I am confident in saying that the Impossible Burger is the safest and most thoroughly safety-tested burger in history. In striking contrast, the alternative, animal-derived burger is one of the least safe and most inadequately tested foods on the market.

And were committed to solving the most urgent threat the world faces today: the use of animals in the food system. Since the small-scale launch of the Impossible Burger, with just 50,000 lbs sold to date (10 billion lbs of ground beef were sold in the same time period), and working with our great restaurant partners, the Impossible Burger has already had an outsized impact: weve had an overwhelmingly positive response from consumers, and weve reduced greenhouse gases emissions by the equivalent of removing 246 American cars from the road for a year, reduced the land footprint of meat production by an area half the size of New Yorks Central Park, saved as much fresh water as 50,000 average Americans drink in a year, and saved more than 100 cows from slaughter. We cant solve this problem unless people love our burger.

Impossible Foods intends to be the most open and transparent company in the world. We welcome every opportunity to answer questions from the public and media, and share our answers on our social media channels. Before deciding how you feel about Impossible Foods or the Impossible Burger, read our story and then decide for yourself.

Continue reading here:
Impossible Burger blowback: Will irrational fears of biotechnology block introduction of sustainable foods? - Genetic Literacy Project

August 11, 2017 - By Linda Rogers

Aug 11 is a positive day so far for BioShares Biotechnology Clinical Trials (NASDAQ:BBC) as the ETF is active during the day after gaining 1.42% to hit $23.65 per share. The exchange traded fund has 23.44 million net assets and 2.75% volatility this month.

Over the course of the day 619 shares traded hands, as compared to an average volume of 11,600 over the last 30 days for BioShares Biotechnology Clinical Trials (NASDAQ:BBC).

The ETF is -32.38% of its 52-Week High and 35.06% of its low, and is currently having ATR of 0.74. This years performance is -25.34% while this quarters performance is 2.78%.

The ETFs YTD performance is 0%, the 1 year is 0% and the 3 year is 0%.

More notable recent BioShares Biotechnology Clinical Trials Fund (NASDAQ:BBC) news were published by: Marketwatch.com which released: BioShares Biotechnology Clinical Trials Fund on December 16, 2014, also Etfdailynews.com with their article: This Tiny Early-Stage Biotech ETF Was Q1s Best Performing Fund published on March 31, 2017, Globenewswire.com published: BioShares Biotechnology ETFs Complete Semi-Annual Rebalance and Recomposition on June 16, 2017. More interesting news about BioShares Biotechnology Clinical Trials Fund (NASDAQ:BBC) were released by: Forbes.com and their article: A More Viable Way To Invest In Top-Performing Biotech Stocks published on August 12, 2015 as well as Etftrends.coms news article titled: Silver Lining for Biotechnology ETFs After Pfizer Calls off Allergan Deal with publication date: April 06, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

View post:
BioShares Biotechnology Clinical Trials (BBC) Rises 1.42% for Aug 11 - BZ Weekly

20th World Congress on Biotechnology and Biotech Industries Meet during March 05-07, 2018 at London, UK with a theme Future prospects for Biotechnology and Economic Growth. Conference Series LLC through its Open Access Initiative is committed to make genuine and reliable contributions to the scientific community.

Scope and Importance

Biotech Congress 2018 Conference aims to bring together the Professors, Researchers, scientists, business giants, and technocrats to provide an international forum for the dissemination of original research results, new ideas and practical development and discover advances in the field of biotechnology, management and education in relation to biotechnology as well as a breadth of other topics. The applications of biotechnology include therapeutics, diagnostics, genetically modified crops for agriculture, processed food, bioremediation, waste treatment, and energy production. Biotech Congress 2018 is an excellent opportunity for the delegates from Universities and Institutes to interact with the world class Scientists.

Like what you just read? You can find similar content on the communities below.

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

See more here:
20th World Congress on Biotechnology and Biotech Industries Meet - Technology Networks

Joe Cox, Ph.D., Bolder BioTechnology's President said: "Initiation of this clinical trial represents a major milestone for Bolder BioTechnology and the culmination of many years of effort by our dedicated and talented employees."

"BBT-015 is a novel G-CSF analog that exhibits a longer duration of action and greater potency than other G-CSF products. In preclinical studies, BBT-015 stimulated larger and longer-lasting increases in neutrophils, and faster neutrophil recovery in chemotherapy-treated, neutropenic animals compared to other G-CSF products.BBT-015 also significantly increased survival and accelerated recovery of neutrophils, platelets, and red blood cells in animals exposed to lethal doses of radiation, even when administered 24 hours following radiation exposure."

"BBT-015's increased potency and longer duration of action may stimulate faster neutrophil recovery in cancer patients and / or allow the drug to be administered less frequently and at lower doses than competing G-CSF products, with associated cost savings for patients."

"G-CSF products are some of the best selling biopharmaceuticals in the world, with annual worldwide sales exceeding $6 billion, primarily from the treatment of neutropenia in cancer patients."

About BBT-015BBT-015 is a long-acting G-CSF analog produced using site-specific PEGylation technology.G-CSF is a human protein that stimulates production of neutrophils, a type of white blood cell that is important for fighting infections.G-CSF has a short half-life in humans and typically is administered to patients by daily injection.BBT-015 has been selectively modified with the polymer polyethylene glycol at a unique site in the protein, which allows the protein to last longer in patients, reducing the need for frequent administration and increasing the protein's ability to stimulate long-lasting production of neutrophils.

About Chemotherapy-Related NeutropeniaNeutropenia (severely reduced numbers of neutrophils) is a common side effect of chemotherapy treatment in cancer patients.Neutropenia increases the patient's risk of developing serious bacterial infection and requiring expensive hospitalization.G-CSF products are commonly administered to cancer patients following chemotherapy to accelerate neutrophil recovery and decrease the length of time that patients are neutropenic.

About Acute Radiation SyndromeAcute Radiation Syndrome, often referred to as radiation sickness, is a collection of illnesses that occurs following exposure to high doses of ionizing radiation within a short period of time, such as might occur following an accident at a nuclear power plant or detonation of a nuclear weapon.Bone marrow, which is responsible for producing new blood cells, is one of the most radiation-sensitive tissues, and subjects acutely exposed to high doses of radiation typically develop bone marrow aplasia and severe neutropenia and thrombocytopenia (low numbers of platelets) within a few weeks of exposure, Many subjects die from infections due to a lack of neutrophils, or from uncontrolled bleeding due to a lack of platelets.

About Bolder BioTechnologyBolder BioTechnology, Inc. is a private company that uses advanced protein engineering technologies to create proprietary human protein pharmaceuticals with enhanced therapeutic properties for the treatment of hematopoietic and endocrine disorders, cancer and infectious diseases. For additional information about Bolder BioTechnology, Inc., please visit our web site at http://www.bolderbio.com.

Government SupportPreclinical research reported in this press release was supported by The National Cancer Institute and The National Institute of Allergy and Infectious Diseases of the National Institutes of Health under awards R43CA078094, R44CA078094, R43AI084288, R44AI084288, andU01AI107340. The content of this press release is solely the responsibility of Bolder BioTechnology and does not necessarily represent the views of the National Institutes of Health.

Forward Looking StatementsStatements contained herein that are not historical facts are forward-looking statements that are subject to a variety of risks and uncertainties.There are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made by the Company.These factors include, but are not limited to: (1) the Company's ability to successfully complete product research and development, including pre-clinical and clinical studies, and commercialization; (2) the Company's ability to obtain required government approvals; (3) the Company's ability to attract and/or maintain manufacturing, sales, distribution and marketing partners; and (4) the Company's ability to develop and commercialize its products before its competitors.

View original content:http://www.prnewswire.com/news-releases/bolder-biotechnology-announces-initiation-of-phase-1-clinical-trial-of-bbt-015-for-treating-neutropenia-and-acute-radiation-syndrome-300498287.html

SOURCE Bolder BioTechnology, Inc.

http://www.bolderbio.com

Follow this link:
Bolder BioTechnology Announces Initiation of Phase 1 Clinical Trial of BBT-015 for Treating Neutropenia and Acute ... - PR Newswire (press release)

Puma Biotechnology, Inc. (NASDAQ:PBYI)market capitalization at present is $3.29B at the rate of $89.95 a share. The firms price-to-sales ratio was noted 0.00 in contrast with an overall industry average of 100.62. Most of the active traders and investors are keen to find ways to compare the value of stocks. The price-to-sales ratio offers a simple approach in this case. They just need to take the companys market capitalization and divide it by the companys total sales over the past 12 months. The lesser the ratio, the more attractive the investment. During the key period of last 5 years, Puma Biotechnology, Inc. (NASDAQ:PBYI) earnings per share growth remained at -44.40%.

How Company Returns Shareholders Value?

Dividends is a reward scheme, that a company presents to its shareholders. There can be various forms of dividends, such as cash payment, stocks or any other form. This payment is usually a part of the profit of the company. A companys dividend is mostly determined by its board of directors and it requires the shareholders approval.Puma Biotechnology, Inc. (NASDAQ:PBYI)for the trailing twelve months paying dividend with the payout ratio of 0.00% to its shareholders. Currently it is offering a dividend yield of 0.00% and a 5 year dividend growth rate of 0.00%. Over the last year Companys shares have been trading in the range of $28.35 and $98.85. However yesterday the stock remained in between $83.13 and $93.95. The stock is above its 52-week low with 217.28% and is in the wake of its 52-week high with -9.00%.

Performance & Technicalities

In the latest week Puma Biotechnology, Inc. (NASDAQ:PBYI) stock volatility was recorded 6.05% which for the previous full month was noted 4.93%. Meanwhile the stock weekly performance was subdued at -5.66%, which was upheld for the month at 2.92%. Likewise, the upbeat performance for the last quarter was 130.64% and for the full year it was 83.42%. Moreover the Companys Year To Date performance was 193.00%. Now a days one of the fundamental indicator used in the technical analysis is called Stochastic %D, Stochastic indicator was created by George Lane. The stochastic is a momentum indicator comparing the closing price of a security to the range of its prices over a fix period of time. The gauge is based on the assumption that if price surges, the closing price tends towards the values that belong to the upper part of the area of price movements in the preceding period. On the other hand if price drops, the contrary is right. For Puma Biotechnology, Inc. (NASDAQ:PBYI), Stochastic %D value stayed at 72.69% for the last 9 days. Considering more the value stands at 79.05% and 79.07% for 14 and 20 days, in that order.

Digital Realty Trust, Inc. (NYSE:DLR)closed at $117.59 a share in the latest session and the stock value rose almost 19.67% since the beginning of this year. The company has managed to keep price to sales ratio of 8.23 against an industry average of 10.53. The price to sales ratio is the ratio of the market value of equity to the sales. This ratio is internally not steady, since the market value of equity is divided by the total revenues of the firm. Its revenue stood at 15.10% a year on average in the period of last five years. Firms net income measured an average growth rate of 10.80%. Following last close companys stock, is 2.09% above their SMA 50 and -3.24% below the 52-week high. A simple moving average (SMA) is an mathematical moving average calculated by adding the closing price of the security for a number of time periods and then dividing this total by the number of time periods. Its most recent closing price has a distance of 4.77% from SMA20 and is 11.48% above than SMA200.

In-Depth Technical Study

Investors generally keep an extensive variety of technical indicators at their disposal for completing technical stock analysis. The average true range is a moving average, generally 14 days, of the true ranges.

The average true range (ATR) was fashioned to allow traders to more precisely evaluate the daily volatility of an asset by using straightforward calculations. However the indicator does not specify the price direction, rather it is used first and foremost to measure volatility caused by gaps and limit up or down moves. The ATR is fairly simple to calculate and only needs historical price data.

ATR is counted for different periods, like 9-day, 14-day, 20-day, 50-day and 100-day. At the moment, the 14-day ATR for Digital Realty Trust, Inc. (NYSE:DLR) is noted at 2.01.

Continue reading here:
Why Investors remained buoyant on: Puma Biotechnology, Inc. (PBYI), Digital Realty Trust, Inc. (DLR) - StockNewsJournal

HYDERABAD: Dr P M Bhargava, eminent scientist and founder-director of the city-based Centre for Cellular and Molecular Biology (CCMB), died here on Tuesday after a brief illness. He was 89 and is survived by two children.

Pushpa Mittra Bhargava was born on February 22, 1928. He was a pioneer in the field of biotechnology in India and among the first persons to use the term "genetic engineering". Bhargava was instrumental in the formation of the Department of Biotechnology in the '70s. He was also chairman of Medically Aware and Responsible Citizens of Hyderabad, Sambhavna Trust, Bhopal, and Basic Research, Education and Development Society (BREAD), New Delhi. He served as vice-chairman of the National Knowledge Commission between 2005 and 2007.

Bhargava received over 100 national and international honours and awards. He was awarded the Padma Bhushan in 1986 but returned it in 2015 citing "matters of principle". He was honoured with the Legion d'honneur in 1998. He is popularly known as the architect of modern biology in India.

Read the rest here:
Dr Pushpa Mitra Bhargava, pioneer in biotechnology, passes away at 89 - Times of India

The August issue of the New Jersey State Bar Association's bi-monthly magazine, New Jersey Lawyer, focuses on the evolving topic of biotechnology, genetics and the law.

"Although a very specialized area, biotechnology law crosses many legal disciplines, including litigation, licensing, intellectual property, patents, agriculture, business, venture capitalism, antitrust, biosecurity and bioethics," said Angela Foster and David Opderbeck, who served as special editors for the issue.

"The use of biotechnology has raised a number of legal, ethical and social issues, including who owns genetically modified organisms (GMOs), whether genetically modified foods are safe to eat, and who controls a person's genetic information. This issue explores contemporary biotechnology issues impacting the legal community."

A dozen articles explore the topic in the award-winning magazine, beginning with a look at whether organs-on-chips are patentable in an article by Douglas Bucklin. Richard Catalina Jr.'s article on the Biologics Price Competition and Innovation Act follows.

Nancy Del Pizzo's article looks at the open source model in biotechnology, while Foster explores the truth and fiction behind genetically modified food. Jonathan Lourie reviews strategic licenses and collaborations.

Reproduction is the topic of two articles, one analyzing assisted reproductive technology, written by Alan Milstein, and one penned by Kimberly Mutcherson on regulating the right to procreate.

Opderbeck's contribution focuses on synthetic biology and biosecurity, while Anjana Patel and Patricia Wagner discuss biotech mergers, acquisitions and antitrust issues and Marina Sigareva and Ryan O'Donnell look at global strategies for protecting biotech inventions.

The edition closes with articles on the Patent Trial and Appeal Board's influence on the biotech and pharma industries, written by Nichole Valeyko and Maegan Fuller, and the privacy implications for biotechnology by Wagner.

The October edition of New Jersey Lawyer will explore pro bono issues.

Follow this link:
NJSBA magazine explores biotechnology and genetics - Yahoo News

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:

Privacy Policy (Updated: October 8, 2015):

hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide

Read the rest here:
NAS Releases Final Report on Preparing for Future Products of Biotechnology - JD Supra (press release)